NIVF Stock Target Surges 400% as Analysts Revise Valuation Estimates

MetaMisfit · 2026-03-03T08:00:48+00:00

Analysts have raised NewGenIvf Group's price target by 400% to $76.50, reflecting increased confidence despite mixed institutional sentiment and a significant decline in holdings among major investors.

MetaMisfit

2026-03-03 08:00:48

Abstract generation in progress

NewGenIvf Group (NIVF) has caught significant analyst attention recently, with consensus price targets climbing dramatically. The latest revision represents a massive 400% jump in valuation estimates among research teams tracking the stock.

Analyst Consensus Jumps 400% from Previous Estimate

Research analysts have unified around a new one-year price target of $76.50 per share, a substantial increase from the prior estimate of $15.30 that was set back in November 2025. The 400% surge in target price reflects heightened confidence in the company’s prospects among financial professionals. Current analyst targets span from a cautious $75.75 to an optimistic $78.75 per share. When compared to NIVF’s latest closing price of $1.45, the consensus target implies over 5,000% upside potential.

Institutional Fund Positioning and Portfolio Changes

Fund sentiment around NewGenIvf Group shows mixed signals in recent months. Currently, three institutional investors and funds report significant positions in NIVF, representing a decline of 50% from the previous quarter. The average portfolio allocation to NIVF across all tracking funds stands at 0.00%, though this metric increased by 84.29% sequentially. More notably, total institutional shareholdings contracted substantially by 96.90% in the last three months, now totaling approximately 0K shares.

Major Shareholders and Institutional Holders

Among prominent institutional players, SBI Securities Co. maintains a position representing 0.03% ownership of the company. Bank Of America holds a smaller stake at 0.00% ownership. These positions reflect the broader institutional sentiment around the stock, where capital allocation decisions appear cautious despite the upgraded price targets from analysts.

The research and data compiled here comes from Fintel, one of the comprehensive investment research platforms serving individual investors, traders, financial advisors, and smaller investment funds globally. Fintel covers fundamentals, analyst reports, ownership structures, fund positioning, and other market metrics to provide investors with detailed market intelligence.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.